p53 dysregulation in myelodysplastic syndrome.

被引：0
|
作者：
Totzke, G [1 ]
Sachinidis, A [1 ]
Vetter, H [1 ]
Ko, Y [1 ]
机构：
[1] Univ Bonn, Med Poliklin, D-53111 Bonn, Germany
来源：
BLOOD | 1998年 / 92卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3809
引用
收藏
页码：190B / 190B
页数：1
相关论文
共 50 条
  • [31] Relationship of p21 Expression and p53 Mutation Status in Acute Myeloid Leukemia and Myelodysplastic Syndrome
    Eskandari, Mohammad
    Goel, Swati
    Verma, Amit
    Albanese, Joseph
    Wang, Yanhua
    MODERN PATHOLOGY, 2017, 30 : 347A - 347A
  • [32] Relationship of p21 Expression and p53 Mutation Status in Acute Myeloid Leukemia and Myelodysplastic Syndrome
    Eskandari, Mohammad
    Goel, Swati
    Verma, Amit
    Albanese, Joseph
    Wang, Yanhua
    LABORATORY INVESTIGATION, 2017, 97 : 347A - 347A
  • [33] WWOX and p53 Dysregulation Synergize to Drive the Development of Osteosarcoma
    Del Mare, Sara
    Husanie, Hussam
    Iancu, Ortal
    Abu-Odeh, Mohammad
    Evangelou, Konstantinos
    Lovat, Francesca
    Volinia, Stefano
    Gordon, Jonathan
    Amir, Gail
    Stein, Janet
    Stein, Gary S.
    Croce, Carlo M.
    Gorgoulis, Vassilis
    Lian, Jane B.
    Aqeilan, Rami I.
    CANCER RESEARCH, 2016, 76 (20) : 6107 - 6117
  • [34] Survivin overexpression in hepatocellular carcinoma is associated with p53 dysregulation
    Rajesh Kannangai
    Jianzhou Wang
    Qiong Z. Liu
    Fikret Sahin
    Michael Torbenson
    International Journal of Gastrointestinal Cancer, 2005, 35 (1): : 53 - 60
  • [35] Immune dysregulation in myelodysplastic syndrome
    Sugimori, Chiharu
    List, Alan F.
    Epling-Burnette, Pearlie K.
    HEMATOLOGY REPORTS, 2010, 2 (01) : 1 - 9
  • [36] Clinical Implications of p53 Dysfunction in Patients with Myelodysplastic Syndromes
    Riva, Elena
    Zampini, Matteo
    Alberto, Termanini
    Dall'Olio, Lorenzo
    Merlotti, Alessandra
    Kulasekararaj, Austin
    Calvi, Michela
    Di Vito, Clara
    Rahal, Daoud
    Bonometti, Arturo
    Croci, Giorgio
    Boveri, Emanuela
    Gianelli, Umberto
    Ponzoni, Maurilio
    Russo, Antonio
    Tinterri, Benedetta
    Re, Francesca
    Sauta, Elisabetta
    Saba, Elena
    Travaglino, Erica
    Ubezio, Marta
    Campagna, Alessia
    Lanino, Luca
    Maggioni, Giulia
    Tentori, Cristina Astrid
    Milanesi, Chiara
    Manes, Nicla
    D'Amico, Saverio
    Ficara, Francesca
    Crisafulli, Laura
    Mavilio, Domenico
    Lugli, Enrico
    Santoro, Armando
    Diez-Campelo, Maria
    Sanz, Guillermo
    Sole, Francesc
    Platzbecker, Uwe
    Santini, Valeria
    Kordasti, Shahram
    Fenaux, Pierre
    Haferlach, Torsten
    Remondini, Daniel
    Gastone, Castellani
    Della Porta, Matteo G.
    BLOOD, 2022, 140 : 4001 - 4004
  • [37] Overexpression of p53 in myelodysplastic syndromes: Correlation with FAB subtypes
    Wang, GS
    Shidham, V
    Kampalath, B
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1999, 112 (04) : 559 - 560
  • [38] DETECTION OF P53 MUTATIONS USING NONRADIOACTIVE SSCP ANALYSIS - P53 IS NOT FREQUENTLY MUTATED IN MYELODYSPLASTIC SYNDROMES (MDS)
    NEUBAUER, A
    BRENDEL, C
    VOGEL, D
    SCHMIDT, CA
    HEIDE, I
    HUHN, D
    ANNALS OF HEMATOLOGY, 1993, 67 (05) : 223 - 226
  • [39] Darbepoetin efficacy in myelodysplastic syndrome.
    Oliva, EN
    Ronco, F
    Danova, M
    Rovati, B
    Dimitrov, BD
    Vincelli, L
    Alati, C
    Nobile, F
    BLOOD, 2004, 104 (11) : 260B - 260B
  • [40] Allelotype analysis of the myelodysplastic syndrome.
    Xie, D
    Hofmann, WK
    Mori, N
    Williamson, I
    Miller, CW
    Hoelzer, D
    Koeffler, HP
    BLOOD, 1998, 92 (10) : 420A - 420A
12345